1357 studies found for:    Doxorubicin (liposomal) OR Doxil[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
21 Completed Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
Condition: AIDS-related Kaposi Sarcoma
Interventions: Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
22 Not yet recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
23 Active, not recruiting Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Veliparib
24 Recruiting Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Anetumab ravtansine (BAY94-9343);   Drug: Pegylated Liposomal Doxorubicin
25 Withdrawn A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Liposomal Doxorubicin/Melphalan/Bortezomib
26 Recruiting T-DM1 and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Trastuzumab and non-pegylated liposomal doxorubicin
27 Recruiting EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
28 Unknown  Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: PLD and Carboplatin
29 Terminated
Has Results
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
Condition: Ovarian Cancer
Interventions: Drug: Liposomal Doxorubicin;   Drug: Topotecan
30 Completed Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
Condition: Resistant Solid Malignancies
Interventions: Drug: Temsirolimus;   Drug: Pegylated liposomal doxorubicin
31 Completed Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Liposomal Doxorubicin
32 Recruiting Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: carboplatin;   Procedure: therapeutic conventional surgery;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
33 Completed TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: TLR8 Agonist VTX-2337;   Other: Diagnostic Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Paclitaxel
34 Terminated Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Telcyta;   Drug: Liposomal Doxorubicin
35 Completed
Has Results
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Female Reproductive Cancer;   Recurrent Breast Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: ixabepilone;   Drug: pegylated liposomal doxorubicin hydrochloride
36 Completed Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma
Condition: Glioblastoma
Intervention: Drug: Pegylated Liposomal Doxorubicine
37 Recruiting Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Condition: Kaposi Sarcoma
Interventions: Drug: liposomal doxorubicin;   Drug: pomalidomide
38 Recruiting Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Selinexor;   Drug: Pegylated Liposomal Doxorubicin;   Drug: Dexamethasone
39 Unknown  A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Intervention: Device: Liposomal Doxorubicin Combined With ifosfamide
40 Completed Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
Condition: Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Drug: M200 (Volociximab);   Drug: Liposomal Doxorubicin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years